Pathology and Veterinary Support for Preclinical Toxicology Studies

该合同的目的是支持开发治疗学计划（DTP）的药物开发工作，并为癌症治疗和诊断部门（DCTD）开展关键活动，以使潜在的候选药物进入临床试验。毒理学研究在完整、健康的实验动物中进行，作为临床前药物开发计划的最后一步。对评价药物产生的病变进行组织学检查是确定药物安全性和毒性以及毒性可逆性的关键终点。 该合同支持NCI的各种功能，包括毒理学研究的独立病理学评估（确保合同实验室之间的质量和一致性）;根据需要为研究提供组织病理学支持;病理学材料和DTP文件的储存库存储;确定治疗性抗体的组织结合特异性;以及执行专门的组织学程序，如免疫组织化学。

The objective of this contract is to support the Developmental Therapeutics Program's (DTP) drug development effort and also perform critical activities for the Division of Cancer Treatment and Diagnosis (DCTD) in order to allow potential drug candidates proceed to clinical trials. Toxicology studies are conducted in intact, healthy, experimental animals as the final step in the preclinical drug development scheme. Histologic examination of lesions produced by the drug under evaluation is a crucial endpoint in the determination of a drug's safety and toxicity and in the reversibility of that toxicity. This contract supports the NCI in a variety of functions including, independent pathology assessment of toxicology studies (assures quality and consistency amongst the contract laboratories); histopathology support for studies as needed; repository storage of pathology materials and DTP documents; determination of tissue binding specificity of therapeutic antibodies; and performance of specialized histologic procedures such as immunohistochemistry.